| [1] |
Betancur PA, Abraham BJ, Yiu YY, et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer[J].Nat Commun,2017,8:14802.
|
| [2] |
Matlung HL,Szilagyi K,Barclay NA,et al.The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer[J].Immunol Rev,2017,276(1):145-164.
|
| [3] |
Ingram JR,Blomberg OS,Sockolosky JT,et al.Localized CD47 blockade enhances immunotherapy for murine melanoma[J].Proc Natl Acad Sci U S A,2017,114(38):10184-10189.
|
| [4] |
Zhang L, Huang H. Targeting the cancer biomarker CD47: a review on the diverse mechanisms of the CD47 pathway in cancer treatment[J].Anticancer Agents Med Chem,2016,16(6):658-667.
|
| [5] |
Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin′s lymphoma[J].N Engl J Med,2018,379(18):1711-1721.
|
| [6] |
Gholamin S,Mitra SS,Feroze AH,et al.Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors[J].Sci Transl Med,2017,9(381):eaaf2968.
|
| [7] |
Wong KK,Li WA,Mooney DJ,et al.Advances in therapeutic cancer vaccines[J].Adv Immunol,2016,130:191-249.
|
| [8] |
Salman B,Zhou DE,Jaffee EM,et al.Vaccine therapy for pancreatic cancer[J].Oncoimmunology,2013,2(12):e26662.
|
| [9] |
Tabi Z,Man S.Challenges for cancer vaccine development[J].Adv Drug Deliv Rev,2006,58(8):902-915.
|
| [10] |
He Y,Tian H,Dai X,et al.Immunogenicity of HER2 vaccine containing p-nitrophenylalanine[J].J China Pharm Univ(中国药科大学学报),2018,49(3):369-375.
|
| [11] |
Tian H,He Y,Song XD,et al.Nitrated T helper cell epitopes enhance the immunogenicity of HER2 vaccine and induce anti-tumor immunity[J].Cancer Lett,2018,430:79-87.
|
| [12] |
Alexander J,Sidney J,Southwood S,et al.Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides[J].Immunity,1994,1(9):751-761.
|
| [13] |
Dokmanovic M,Wu WJ.Monitoring trastuzumab resistance and cardiotoxicity:A tale of personalized medicine[J].Adv Clin Chem,2015,70:95-130.
|
| [14] |
Gulley JL,Drake CG.Immunotherapy for prostate cancer:recent advances,lessons learned,and areas for further research[J].Clin Cancer Res,2011,17(12):3884-3891.
|
| [15] |
Sonpavde G,Agarwal N,Choueiri TK,et al.Recent advances in immunotherapy for the treatment of prostate cancer[J].Expert Opin Biol Ther,2011,11(8):997-1009.
|
| [16] |
Grivennikov SI,Greten FR,Karin M.Immunity,inflammation,and cancer[J].Cell,2010,140(6):883-899.
|
| [17] |
Datta J,Fracol M,McMillan MT,et al.Association of depressed anti-HER2 T-helper type 1 response with recurrence in patients with completely treated HER2-positive breast cancer:role for immune monitoring[J].JAMA Oncol,2016,2(2):242-246.
|
| [18] |
Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes[J].Cancer Res,2010,70(21):8368-8377.
|
| [19] |
Mlecnik B,Bindea G,Kirilovsky A,et al.The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis[J].Sci Transl Med,2016,8(327):327ra26.
|
| [20] |
Facciabene A,Motz GT,Coukos G.T-regulatory cells:key players in tumor immune escape and angiogenesis[J].Cancer Res,2012,72(9):2162-2171.
|
| [21] |
Valzasina B, Piconese S, Guiducci C, et al. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25-lymphocytes is Thymus and proliferation independent[J].Cancer Res,2006,66(8):4488-4495.
|
下载:
